Structure of the homodimeric androgen receptor ligand-binding domain
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) plays a crucial role in normal physiology, development and metabolism as well as in the aetiology and treatment of diverse pathologies such as androgen insensitivity syndromes (AIS), male infertility and prostate cancer (PCa). Here we show that dimerization of AR ligand-binding domain (LBD) is induced by receptor agonists but not by antagonists. The 2.15-Å crystal structure of homodimeric, agonist- and coactivator peptide-bound AR-LBD unveils a 1,000-Å 2 large dimerization surface, which harbours over 40 previously unexplained AIS- and PCa-associated point mutations. An AIS mutation in the self-association interface (P767A) disrupts dimer formation in vivo , and has a detrimental effect on the transactivating properties of full-length AR, despite retained hormone-binding capacity. The conservation of essential residues suggests that the unveiled dimerization mechanism might be shared by other nuclear receptors. Our work defines AR-LBD homodimerization as an essential step in the proper functioning of this important transcription factor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A symmetric dimeric AR LBD structure was also solved recently (Nadal et al., 2017), suggesting that AR may form a dimer similar to the way ERα dimerizes.”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Nadal et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“the Entrenched state is the most compact, exhibiting the best fit for the X-ray structure of a LBD dimer (Nadal et al., 2017), whereas the extended conformation in the Divorced state deviates the most”
From Allosteric interactions prime androgen receptor dimerization and activation (2022) · cites this paper as Nadal et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., Consler, T. G., Parks, D. J., Stewart, E. L., Willson, T. M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00817-6 · Cited by 818
Allostery in Disease and in Drug Discovery
Nussinov, R., & Tsai, C.-J. (2013) · Cell · doi:10.1016/j.cell.2013.03.034 · Cited by 761
Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains
Tanenbaum, D. M., Wang, Y., Williams, S. P., & Sigler, P. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.5998 · Cited by 738
CUPSAT: prediction of protein stability upon point mutations
Parthiban, V., Gromiha, M. M., & Schomburg, D. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl190 · Cited by 695
Atomic structure of progesterone complexed with its receptor
Williams, S. P., & Sigler, P. B. (1998) · Nature · doi:10.1038/30775 · Cited by 659
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Cited by
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051359 · Cited by 254
“In the cell nucleus, the dimerized AR recognizes cognate DNA response elements in regulatory regions located in proximal or more distal intra- and intergenic regions of androgen target genes [4,5].”
BackgroundStructural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0001-z · Cited by 216
Nuclear receptor crosstalk — defining the mechanisms for therapeutic innovation
De Bosscher, K., Desmet, S. J., Clarisse, D., Estébanez-Perpiña, E., & Brunsveld, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0349-5 · Cited by 199
Self-citationAndrogen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 193
“SRC, steroid receptor coactivator; ARA, AR-associated protein; AF1, activation function 1; AF2, activation function 2, a hydrophobic cleft in the LBD; ARE, androgen response element; DBD, DNA binding domain; LBD, ligand binding domain.”
BackgroundInfluentialAndrogen insensitivity syndrome: a review
Batista, R. L., Costa, E. M. F., Rodrigues, A. D. S., Gomes, N. L., Faria, J. A., Nishi, M. Y., Arnhold, I. J. P., Domenice, S., & Mendonca, B. B. D. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000031 · Cited by 186
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes
Yu, X., Yi, P., Hamilton, R. A., Shen, H., Chen, M., Foulds, C. E., Mancini, M. A., Ludtke, S. J., Wang, Z., & O’Malley, B. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.031 · Cited by 154
Second generation androgen receptor antagonists and challenges in prostate cancer treatment
Chen, Y., Zhou, Q., Hankey, W., Fang, X., & Yuan, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05084-1 · Cited by 169
“Beyond targeting alternative AR domains, another strategy to overcome resistance conferred by point mutations in the LBD is the structure-based design of novel AR antagonists to specifically disrupt LBD dimerization, as AR transactivation potential requires LBD-mediated homodimer formation, regardless of the presence…”
BackgroundFontana, F., Raimondi, M., Marzagalli, M., Domizio, A. D., & Limonta, P. (2020) · Cells · doi:10.3390/cells9020460 · Cited by 114
“Then, the dimerized receptor recognizes cognate DNA response elements in regulatory regions located in proximal or more distal intra- and inter-genic regions of androgen target genes [15,16].”
BackgroundDarolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
Sugawara, T., Baumgart, S. J., Nevedomskaya, E., Reichert, K., Steuber, H., Lejeune, P., Mumberg, D., & Haendler, B. (2019) · International Journal of Cancer · doi:10.1002/ijc.32242 · Cited by 95
“For the AR N/C interaction assay, HCT-116 cells were seeded into 6-well plates and transfected 1 day later with 2 μg of pFR-Luc reporter vector, and 250 ng of pCMV-AD-AR (2-554) and pCMV-BD-AR(665-918) plasmids.”
MethodA magic drug target: Androgen receptor
Li, D., Zhou, W., Pang, J., Tang, Q., Zhong, B., Shen, C., Li, X., & Hou, T. (2018) · Medicinal Research Reviews · doi:10.1002/med.21558 · Cited by 91
“Recently, the first crystal structure of the Homo sapiens AR LBD homodimer bound with DHT was reported.(42) The newly clarified homodimeric structure of the AR LBD demonstrates a canonical head‐to‐head configuration with both the AF2 sites facing opposite directions.”
BackgroundMessner, E. A., Steele, T. M., Tsamouri, M. M., Hejazi, N., Gao, A. C., Mudryj, M. M., & Ghosh, P. (2020) · Biomedicines · doi:10.3390/biomedicines8100422 · Cited by 99
“LB -LB ho odi erization of R induced by receptor agonists, such as activating ligands, is an essential step in the proper functioning of the AR [24].”
BackgroundInfluentialHussain, Y., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., Hushmandi, K., Khan, H. Z., & Daglia, M. (2021) · Cancers · doi:10.3390/cancers13071602 · Cited by 88
Rational optimization of a transcription factor activation domain inhibitor
Basu, S., Martínez-Cristóbal, P., Frigolé-Vivas, M., Pesarrodona, M., Lewis, M., Szulc, E., Bañuelos, C. A., Sánchez-Zarzalejo, C., Bielskutė, S., Zhu, J., et al. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01159-5 · Cited by 83
“Such splice variants lack a LBD and consist of only a DNA-binding domain (DBD) and an intrinsically disordered activation domain (AD), rendering them insensitive to LBD-targeting anti-androgens 9–12 .”
InfluentialEnzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. T., & Preković, S. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0289 · Cited by 85
Xu, L., Yin, Y., Li, Y., Chen, X., Chang, Y., Zhang, H., Liu, J., Beasley, J., McCaw, P., Zhang, H., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012748118 · Cited by 87
“AR is a physiological molecule and a key transcription factor in multiple organs which binds to numerous genes and activates many different downstream signaling pathways (4, 7, 8).”
BackgroundAndrogens, oestrogens and endometrium: a fine balance between perfection and pathology
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2020) · Journal of Endocrinology · doi:10.1530/joe-20-0106 · Cited by 76
Akacha, A., Badraoui, R., Rebaï, T., & Zourgui, L. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1856187 · Cited by 74
“As an AR, the MTX-5JJM is involved in the etiology of diverse male pathology including prostate cancer, androgen insensitivity syndromes (AIS) and infertility (Nadal et al., 2017).”
BackgroundMolecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
Elshan, N. G. R. D., Rettig, M. B., & Jung, M. E. (2018) · Medicinal Research Reviews · doi:10.1002/med.21548 · Cited by 71
Mohler, M. L., Sikdar, A., Ponnusamy, S., Hwang, D., He, Y., Miller, D. D., & Narayanan, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042124 · Cited by 74
“Noncompetitive antagonists are reported for the following noncanonical sites: (1) activating function (AF)-2 and (2) binding function-3 (BF-3) sites that reside in the LBD, DBD sites include (3) the DNA recognition helix [55] and (4) the DBD/dimerization region (not discussed here, but reported) [56,57], and (5) AF-1…”
BackgroundZhang, Y., Ming, A., Wang, J., Chen, W., & Fang, Z. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107234 · Cited by 72
Structural and molecular determinants of mineralocorticoid receptor signalling
Großmann, C., Almeida‐Prieto, B., Nolze, A., & de la Rosa, D. Á. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15746 · Cited by 66
Chen, L., Han, L., Mao, S., Xu, P., Xu, X., Zhao, R., Wu, Z., Zhong, K. L., Yu, G., & Wang, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113307 · Cited by 53
The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation
Kharraz, S. E., Dubois, V., van Royen, M. E., Houtsmuller, A. B., Pavlova, E., Atanassova, N. N., Nguyen, T., Voet, A. R. D., Eerlings, R., Handle, F., et al. (2021) · EMBO Reports · doi:10.15252/embr.202152764 · Cited by 54
“Here, we introduced a mutation (hW752R/mW731R) that disrupts the LBD dimerization without major effect on the LBD 3D structure (Nadal et al , 2017).”
InfluentialSelf-citationEighty Years of Targeting Androgen Receptor Activity in Prostate Cancer: The Fight Goes on
Estébanez‐Perpiñá, E., Bevan, C. L., & McEwan, I. J. (2021) · Cancers · doi:10.3390/cancers13030509 · Cited by 57
“However, this “simple” monomer–dimer equilibrium transition model is being challenged by ongoing research, and important questions remain regarding the possible additional role of chaperone proteins [23–26], the cellular location of dimerization [15,27,28] and the influence of response element architecture on receptor…”
BackgroundSelf-citationAllosteric interactions prime androgen receptor dimerization and activation
Wasmuth, E. V., Broeck, A. V., LaClair, J. R., Hoover, E. A., Lawrence, K. E., Paknejad, N., Pappas, K., Matthies, D., Wang, B., Feng, W., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.03.035 · Cited by 50
“While all three models share this common dimerization interface, the Entrenched state is the most compact, exhibiting the best fit for the X-ray structure of a LBD dimer (Nadal et al., 2017), whereas the extended conformation in the Divorced state deviates the most (Fig.”
BackgroundBurris, T. P., de Vera, I. M. S., Côté, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., Walker, J. K., Steinauer, N., Zhang, J., Coons, L. A., et al. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000436 · Cited by 56
Dalal, K., Ban, F., Li, H., Morin, H., Roshan‐Moniri, M., Tam, K. J., Shepherd, A., Sharma, A., Peacock, J. W., Carlson, M. L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.016 · Cited by 51
Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease
Arnold, F. J., & Merry, D. E. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00790-9 · Cited by 54
Nuclear receptor phosphorylation in xenobiotic signal transduction
Negishi, M., Kobayashi, K., Sakuma, T., & Sueyoshi, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.007933 · Cited by 56
Therapeutic Strategies to Target the Androgen Receptor
Xiang, W., & Wang, S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00716 · Cited by 51
Kaempferol inhibits benign prostatic hyperplasia by resisting the action of androgen
Wang, X., Zhu, J., Yan, H., Shi, M., Zheng, Q., Wang, Y., Zhu, Y., Miao, L., & Gao, X. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174251 · Cited by 49
Thiyagarajan, T., Ponnusamy, S., Hwang, D., He, Y., Asemota, S., Young, K. L., Johnson, D. L., Bocharova, V., Zhou, W., Jain, A. K., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211832120 · Cited by 52
Harris, A. E., Metzler, V. M., Lothion‐Roy, J. H., Varun, D., Woodcock, C. L., Haigh, D. B., Endeley, C., Haque, M., Toss, M. S., Alsaleem, M. A., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1006101 · Cited by 55
“The AR homodimer usually is a “head-to-head” formation (18) and preferentially binds to the androgen response element (ARE) on the DNA (19, 20).”
BackgroundSafi, R., Wardell, S. E., Watkinson, P., Qin, X., Lee, M., Park, S., Krebs, T., Dolan, E. L., Blattler, A., Tsuji, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52032-y · Cited by 50
“To probe the roleof dimerization inLD/HD androgen signaling we fi rst recreated previouslydescribed AR mutants that have been reported to interfere with dimerization 43 .”
Androgen Physiology: Receptor and Metabolic Disorders
McEwan, I. J., & Brinkmann, A. O. (2016) · Cited by 46
Conformational dynamics of androgen receptors bound to agonists and antagonists
Gim, H. J., Park, J., Jung, M. E., & Houk, K. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-94707-2 · Cited by 45
Jin, Y., Duan, M., Wang, X., Kong, X., Zhou, W., Sun, H., Liu, H., Li, D., Yu, H., Li, Y., et al. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00796 · Cited by 42
Androgen signalling in the ovaries and endometrium
Lissaman, A. C., Girling, J. E., Cree, L. M., Campbell, R. E., & Ponnampalam, A. P. (2023) · Molecular Human Reproduction · doi:10.1093/molehr/gaad017 · Cited by 45
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Parolia, A., Eyunni, S., Verma, B. K., Young, E., Liu, Y., Liu, L., George, J. M., Aras, S., Das, C. K., Mannan, R., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01893-6 · Cited by 47
Zariquiey, F. S., de Souza, J. V. B., & Bronowska, A. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55394-2 · Cited by 37
Molecular underpinnings of enzalutamide resistance
Preković, S., den Broeck, T. V., Linder, S., van Royen, M. E., Houtsmuller, A. B., Handle, F., Joniau, S., Zwart, W. T., & Claessens, F. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0136 · Cited by 39
Self-citationACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 40
“AR-V7 lacks the ligandbinding domain (LBD) and thus is insensitive to the levels of anti-androgens in the tumor milieu (22).”
BackgroundInfluentialJiménez‐Panizo, A., Alegre‐Martí, A., Tettey, T. T., Fettweis, G., Abella, M., Antón, R. I., Johnson, T. A., Kim, S., Schiltz, R. L., Barrios-Núñez, I., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1119 · Cited by 33
Self-citationBadraoui, R., Gargouri, M., Brahmi, F., Ben‐Nasr, H., Bahrini, I., & Soussi, A. (2024) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.14024 · Cited by 36
Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer
Asangani, I. A., Blair, I. A., Duyne, G. D. V., Hilser, V. J., Moiseenkova‐Bell, V. Y., Plymate, S. R., Sprenger, C. C. T., Wand, A. J., & Penning, T. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.012411 · Cited by 35
Zhang, Z., Connolly, P. J., Lim, H. K., Pande, V., Meerpoel, L., Teleha, C. A., Branch, J. R., Ondrus, J., Hickson, I., Bush, T. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01563 · Cited by 31
Van-Duyne, G., Blair, I. A., Sprenger, C. C. T., Moiseenkova‐Bell, V. Y., Plymate, S. R., & Penning, T. M. (2023) · Vitamins and hormones · doi:10.1016/bs.vh.2023.01.001 · Cited by 32
Structural determinants of activation of the mineralocorticoid receptor: an evolutionary perspective
Fuller, P. J., Yao, Y.-Z., Yang, J., & Young, M. J. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0360-2 · Cited by 34
Chaturvedi, A. P., & Dehm, S. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_15 · Cited by 36
Bezerra, K. S., Vianna, J. F., Neto, J. X., Oliveira, J. I. N., Albuquerque, E. L., & Fulco, U. L. (2020) · New Journal of Chemistry · doi:10.1039/c9nj06276a · Cited by 28
Jiménez‐Panizo, A., Pérez, P., Rojas, A. M., Fuentes‐Prior, P., & Estébanez‐Perpiñá, E. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0132 · Cited by 32
Self-citationChen, Q., Tan, H., Yu, H., & Shi, W. F. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.03.003 · Cited by 35
Chen, Q., Wang, X., Tan, H., Shi, W. F., Zhang, X., Wei, S., Giesy, J. P., & Yu, H. (2019) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.9b00073 · Cited by 27
“36,37 BPBP, BPC, and BPPH caused mode B repositioning (Figure 1 and Table 1), which resulted in blocking of both CoA and CoR.”
Shizu, R., Min, J., Sobhany, M., Pedersen, L. C., Mutoh, S., & Negishi, M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806604 · Cited by 29
Structural basis for heme-dependent NCoR binding to the transcriptional repressor REV-ERBβ
Mosure, S. A., Strutzenberg, T. S., Shang, J., Munoz‐Tello, P., Solt, L. A., Griffin, P. R., & Kojetin, D. J. (2021) · Science Advances · doi:10.1126/sciadv.abc6479 · Cited by 25
Small-Molecule Inhibition of Androgen Receptor Dimerization as a Strategy against Prostate Cancer
Fu, W., Yang, H. C., Hu, C., Liao, J., Gong, Z., Zhang, M., Yang, S., Ye, S., Lei, Y., Sheng, R., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01548 · Cited by 26
Phenotypic and molecular characteristics of androgen insensitivity syndrome patients
Tan, Y., Yuan, S., Zhang, Y., Du, J., Li, W., Tu, C., Meng, L., Lin, G., & Lu, G. (2018) · Asian Journal of Andrology · doi:10.4103/aja.aja_17_18 · Cited by 26
Advances in the computational development of androgen receptor antagonists
Hu, X., Chai, X., Wang, X., Duan, M., Pang, J., Fu, W., Li, D., & Hou, T. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.004 · Cited by 25
Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC
Ji, Y., Zhang, R., Han, X., & Zhou, J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115077 · Cited by 25
Transcriptional and Post-Transcriptional Regulations of Amyloid-β Precursor Protein (APP) mRNA
Sato, K., Takayama, K., Hashimoto, M., & Inoue, S. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.721579 · Cited by 26
“After ligand binding, the AR homodimer translocates into the nucleus, where it binds to the androgen-responsive element (ARE), and subsequently activates gene expression often with epigenetic changes in the chromatin state (Tewari et al., 2012; Nevedomskaya et al., 2016; Nadal et al., 2017; Stelloo et al., 2019).”
BackgroundFu, W., Zhang, M., Liao, J., Tang, Q. H., Lei, Y., Gong, Z., Shan, L., Duan, M., Chai, X., Pang, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01287 · Cited by 22
SPOP-mutant prostate cancer: Translating fundamental biology into patient care
Bernasocchi, T., & Theurillat, J.-P. P. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.024 · Cited by 23
Lek, N., Tadokoro‐Cuccaro, R., Whitchurch, J. B., Mazumder, B., Miles, H. L., Prentice, P. M., Bunch, T., Zielińska, K. A., Metzler, V. M., Mongan, N. P., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.047 · Cited by 22
“The Y916 residue does not participate in the cofactor binding site, nor at the recently characterised AR dimerization interface [18].”
BackgroundMalhotra, S., Alsulami, A. F., Heiyun, Y., Ochoa‐Montaño, B., Jubb, H. C., Forbes, S. A., & Blundell, T. L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219935 · Cited by 23
“AR has two main domains: ligand-binding domain (LBD, residue range: 668–918)[53], which binds 5-α dihydrotestosterone (DHT) and activates downstream signaling including phosphorylation of the second messenger signaling cascade and DNA-binding domain (DBD residue range: 538–629) [54], which regulates the target gene ex…”
Steroid receptor-coregulator transcriptional complexes: new insights from CryoEM
Yi, P., Yu, X., Wang, Z., & O’Malley, B. W. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210019 · Cited by 24
Adamson, B., Brittain, N., Walker, L., Duncan, R., Luzzi, S., Rescigno, P., Smith, G., McGill, S., Burchmore, R., Willmore, E., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci169200 · Cited by 22
“The AR comprises an N-terminal transactivation domain (NTD), a DNA-binding domain (DBD), and a C-terminal ligand-binding domain (LBD), with a hinge region separating the DBD and LBD (3, 4).”
Alegre‐Martí, A., Jiménez‐Panizo, A., Martínez-Tébar, A., Poulard, C., Peralta-Moreno, M. N., Abella, M., Antón, R. I., Chiñas, M., Eckhard, U., Piulats, J. M., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade2175 · Cited by 20
Self-citationAlternative dimerization interfaces in the glucocorticoid receptor-α ligand binding domain
Bianchetti, L., Waßmer, B., Defosset, A., Smertina, A., Tiberti, M. L., Stote, R. H., & Dejaegere, A. P. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.04.022 · Cited by 21
Liu, Q., Yin, X., & Li, P. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01894-4 · Cited by 18
“Patients with the p.Gln60*, p.Arg841His, and p.Arg856His variants developed CAIS and PAIS.”
InfluentialPreković, S., den Broeck, T. V., Moris, L., Smeets, E., Claessens, F., Joniau, S., Helsen, C., & Attard, G. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.08.020 · Cited by 18
Self-citationZhang, C., Wu, J., Chen, Q., Tan, H., Huang, F., Guo, J., Zhang, X., Yu, H., & Shi, W. F. (2021) · Environment International · doi:10.1016/j.envint.2021.107009 · Cited by 19
Chen, Y., & Lan, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1451957 · Cited by 25
Diversity of Quaternary Structures Regulates Nuclear Receptor Activities
Fuentes‐Prior, P., Rojas, A. M., Hagler, A. T., & Estébanez‐Perpiñá, E. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.005 · Cited by 18
Self-citationLigand induced dissociation of the AR homodimer precedes AR monomer translocation to the nucleus
Shizu, R., Yokobori, K., Perera, L., Pedersen, L. G., & Negishi, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-53139-9 · Cited by 16
Yu, G., Liu, X., Zhang, D., Wang, J., Ouyang, G., Chen, Z., & Xiao, W. (2020) · Development · doi:10.1242/dev.194886 · Cited by 17
Chukhu, M., Dahiya, U. R., & Heemers, H. V. (2025) · Oncogene · doi:10.1038/s41388-025-03573-z · Cited by 26
“…conformation of AR transcriptional complexes has been derived from in vitro X-Ray, crystallography or computational modeling of individual DBD or LBD domains that are associated with small peptides from AR-associated proteins in the presence of a few agonists or antagonists [44, 51, 82 – 90].”
Zhang, D., Yao, F., Tian, T., Deng, S., Luo, M., & Tian, Q. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.12.008 · Cited by 16
Application of a stepwise frontal analysis method in cell membrane chromatography
He, X., Sui, Y., & Wang, S. (2020) · Journal of Chromatography B · doi:10.1016/j.jchromb.2020.122436 · Cited by 15
Glucocorticoid receptor dimerization in the cytoplasm might be essential for nuclear localization
Lee, S., Shizu, R., & Negishi, M. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.03.071 · Cited by 15
Lee, S., Hong, K. Y., Seo, H., Lee, H., & Park, Y. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109655 · Cited by 15
Phosphorylation of nuclear receptors: Novelty and therapeutic implications
Shindo, S., Kakizaki, S., Sakaki, T., Kawasaki, Y., Sakuma, T., Negishi, M., & Shizu, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108477 · Cited by 14
Liao, J., Liao, J., Zhang, M., Yu, Y., Cai, L., Le, K., Fu, W., Qin, Y., Hou, T., Li, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01752 · Cited by 15
Rayevsky, A. V., Sirokha, D., Samofalova, D. O., Ложко, Д. М., Gorodna, O., Prokopenko, I., & Лившиц, Л. А. (2021) · Life · doi:10.3390/life11070659 · Cited by 14
“At the same time, a notable destabilization of multiple side chains and disordered loops of a single molecule of wild-type protein takes place (Figure 1A,B) [38].”
BackgroundExploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors
Helsen, C., Nguyen, T. T., Lee, X. Y., Eerlings, R., Louros, N. N., Schymkowitz, J. W. H., Rousseau, F., Claessens, F., & Voet, A. R. D. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0340 · Cited by 13
Self-citationDiscovery of Novel Anti‐Resistance AR Antagonists Guided by Funnel Metadynamics Simulation
Chen, H., Zhou, Y., Wang, X., Chai, X., Wang, Z., Wang, E., Xu, L., Hou, T., Li, D., & Duan, M. (2024) · Advanced Science · doi:10.1002/advs.202309261 · Cited by 13
α-Terthienyl induces prostate cancer cell death through inhibiting androgen receptor expression
Gan, X., Huang, H., Wen, J., Liu, K., Yang, Y., Li, X., Fang, G., Liu, Y., & Wang, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113266 · Cited by 16
Majeed, A., Qamar, M. T. U., Maryam, A., Mirza, M. U., Alhussain, L., Otaibi, S. O. A., Almatroudi, A., Allemailem, K. S., Alrumaihi, F., Aloliqi, A. A., et al. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2208203 · Cited by 13
“In that event, a catalytic competent conformation evolves in which a functional coactivator binding site appears after the rearrangement of the activation function (AF-2) residues in LBD. AF-2 residues crucial for transactivation are clustered over the surface of H 3 , H 4 and H 12 .”
BackgroundInfluentialPaquin, A., Oufqir, Y., Sevrioukova, I. F., Reyes‐Moreno, C., & Bérubé, G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113496 · Cited by 14
Chemical modulation of transcription factors
Wiedemann, B. M., Weisner, J., & Rauh, D. (2018) · MedChemComm · doi:10.1039/c8md00273h · Cited by 12
Kong, X., Xing, E., Zhuang, T., Li, P., & Cheng, X. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00124 · Cited by 12
Recent advances in dietary androgen receptor inhibitors
Ren, L., Zhang, T., & Zhang, J. (2024) · Medicinal Research Reviews · doi:10.1002/med.22019 · Cited by 14
Park, C. G., Adnan, K. M., Cho, H., Ryu, C. S., Yoon, J., & Kim, Y. J. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105838 · Cited by 15
Androgen receptor inhibitors in treating prostate cancer
Cole, R. N., Fang, Q., Matsuoka, K., & Wang, Z. (2024) · Asian Journal of Andrology · doi:10.4103/aja202494 · Cited by 15
“56 N/C interactions and these cofactors have also been implicated in vitro for regulating AR stability and increasing AR DNA-binding affinity.”
DNA binding alters ARv7 dimer interactions
Özgün, F., Kaya, Z., Morova, T., Geverts, B., Abraham, T. E., Houtsmuller, A. B., van Royen, M. E., & Lack, N. A. (2021) · Journal of Cell Science · doi:10.1242/jcs.258332 · Cited by 12
Self-citationXia, Q., Zhang, S.-H., Zeng, N., Lu, Y., Qin, B., & Wang, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115806 · Cited by 12
Development of a Novel Amplifiable System to Quantify Hydrogen Peroxide in Living Cells
Wang, L., Lin, H., Yang, B. T., Jiang, X., Chen, J., Chowdhury, S. R., Cheng, N., Nakata, P. A., Lonard, D. M., Wang, M. C., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05366 · Cited by 10
The multimerization pathway of the glucocorticoid receptor
Alegre‐Martí, A., Jiménez‐Panizo, A., Lafuente, A. L., Johnson, T. A., Montoya-Novoa, I., Peralta-Moreno, M. N., Montanyà-Valluguera, P., Ponsetí-Pons, J., Abella, M., Kim, S., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1003 · Cited by 11
Self-citationKanemoto, Y., Iwaki, M., Sawada, T., Nojiri, K., Kurokawa, T., Tsutsumi, R., Nagasawa, K., & Kato, S. (2023) · Journal of Bone Metabolism · doi:10.11005/jbm.2023.30.3.219 · Cited by 10
“Structural analyses have shown that the binding of synthetic ligands shifts α-helix 12 of NRs to an angle distinct from that achieved upon cognate hormone binding, leading us to propose ligand type-specific conformational alterations over the entire receptor protein.[45,46] X-ray crystallographic analyses of the ER-α…”
BackgroundTargeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer
Hantusch, B., Kenner, L., Stanulović, V. S., Hoogenkamp, M., & Brown, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179245 · Cited by 12
“Recent crystal structure data indicate a high flexibility of the core AR dimers which might form a head-to-tail or a head-to-head arrangement [40].”
BackgroundLu, T., Zheng, W., Lei, Y., Hu, F., Li, M., & Guo, L. (2025) · Environment & Health · doi:10.1021/envhealth.4c00240 · Cited by 10
Metadata
- Authors
- Nadal, M., Prekovic, S., Gallastegui, N., Helsen, C., Abella, M., Zielinska, K., Gay, M., Vilaseca, M., Taulès, M., Houtsmuller, A. B., van Royen, M. E., Claessens, F., Fuentes-Prior, P., & Estébanez-Perpiñá, E.
- Affiliations
- Agència de Gestió d'Ajuts Universitaris i de Recerca (ES)
- KU Leuven (BE)
- Institute for Research in Biomedicine (ES)
- Erasmus MC (NL)
- ORCID
- Venue
- Nature Communications
- Published
- 2017-02-06
- Volume
- 8
- Issue
- 1
- Pages
- 14388-14388
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5303882
- OpenAlex
- W2586987557
- Cited by
- 193
- References
- 59
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 30 · 2023: 21 · 2022: 22 · 2021: 32 · 2020: 21 · 2019: 13 · 2018: 17 · 2017: 5
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Lirias (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Generalitat de Catalunya
- Fonds Wetenschappelijk Onderzoek (G068412N, GOA/15/017, G083013N)
- KU Leuven (GOA/15/017)
- Kom op tegen Kanker
- Vlaamse regering
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- androgen receptor, ligand-binding domain, homodimerization, crystal structure, coactivator peptide, androgen insensitivity syndrome, prostate cancer, point mutations, transcriptional activation, nuclear receptors, transcription factors
- MeSH terms
- Protein Domains, Androgens, Animals, Chlorocebus aethiops, Humans, Ligands, Male, Models, Molecular, Prostatic Neoplasms, Receptors, Androgen, Androgen-Insensitivity Syndrome, Point Mutation, Crystallography, X-Ray, COS Cells, Surface Plasmon Resonance, Protein Structure, Quaternary, Ubiquitin-Activating Enzymes, Cell Line, Tumor, Protein Multimerization, Androgen Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.